Susquehanna International Group’s Acrivon Therapeutics ACRV Stock Holding History

Susquehanna International Group’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,433	Closed	-$30K	–	13072
2025 Q4	$30K	Buy	+12,433	New	+$27K	﹤0.01%	11873
2025 Q3	–	Sell	-43,860	Closed	-$52.2K	–	12240
2025 Q2	$52.2K	Buy	43,860 +29,280	+201%	+$40.2K	﹤0.01%	12097
2025 Q1	$29.6K	Buy	+14,580	New	+$78.5K	﹤0.01%	12015
2023 Q2	–	Sell	-32,262	Closed	-$409K	–	11946
2023 Q1	$409K	Buy	+32,262	New	+$542K	﹤0.01%	9043

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's ACRV Position: Q1 2026 in Review

Susquehanna International Group sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 12,433 shares — an estimated $30K sold.

Susquehanna International Group first reported a position in ACRV in Q1 2023 and held it in 4 quarters. The position peaked at $409K in Q1 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Susquehanna International Group reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 12,433 Acrivon Therapeutics shares in Q1 2026, an estimated $30K.
Susquehanna International Group first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 4 quarters.
Susquehanna International Group's Acrivon Therapeutics position peaked at $409K in Q1 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.